Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: nhhick who wrote (737)	3/12/1998 11:29:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

This found from another thread --- FROM AOL: Abbott presented at the Cowan health care conference on March 11. ABT was asked numerous questions about theri pipeline and there many collaborations and partnerships. When discussing the hospital products division they were asked about the relationship with BTIM and specifically about Hextend. They explained how the hospital products division had changed over the years to include not only IV fluids but also IV medications etc. Most importantly they stated they viewed Hextend as a valuable addition to the product line and that Hextend would serve to expand the market. They also stated that they anticipated market launch of Hextend by year end 98. This is not coming from an analyst, this is not coming from the company, this is coming from a very conservative big pharmaceutical partner. If ABT says that they are going to expand the market with the introduction of Hextend and they are going to put there several hundred person sales force behind this product, i suspect this product will be quite successful. ABT went to great lengths to speak about where the growth was going to come from within the company and clearly one of the engines for growth will be Hextend. If ABT is stating publically that the product will be introduced by year end, it is safe to suspect they have some insights on the regulatory process going forward. Despite all of the background noise and misinformation If ABT says this product will expand the market and contribute to growth within the hospital products division, I bet they will make it happen. I was disapointed that I did not see Asensio, or Jesse Eisinger, etc in the audience. The last time this stock ran it put on 20 points in a heart beat. With another peer reviewed paper coming, a presentation in Belgium next week, an FDA filing this month, and 1/3 of the float short, smart money says this stock is going up.